Entrada Therapeutics (TRDA) EBITDA (2020 - 2026)

Entrada Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$40.1 million for Q1 2026.

• In Q1 2026, EBITDA fell 137.85% year-over-year to -$40.1 million; the TTM figure through Mar 2026 stood at -$166.3 million (down 753.11% YoY), while the FY2025 annual figure was -$143.1 million, down 318.78% from the prior year.
• EBITDA was -$40.1 million for Q1 2026 at Entrada Therapeutics, down from -$39.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $54.9 million in Q2 2024 to a low of -$43.9 million in Q3 2025.
• Historically, EBITDA has averaged -$12.9 million across 5 years, with a median of -$23.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 538.39% in 2024, then sank 33835.34% in 2025.
• A 5-year view of EBITDA shows it stood at -$23.9 million in 2022, then jumped by 63.02% to -$8.9 million in 2023, then surged by 101.31% to $116000.0 in 2024, then tumbled by 33835.34% to -$39.1 million in 2025, then fell by 2.53% to -$40.1 million in 2026.
• The last three EBITDA figures came in at -$40.1 million (Q1 2026), -$39.1 million (Q4 2025), and -$43.9 million (Q3 2025), per Business Quant data.